seq.trans-2.6-Dimethyl-2-epoxy-6-octen | 55874-06-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 环氧化物
• 英文名称: seq.trans-2.6-Dimethyl-2-epoxy-6-octen
• 英文别名: 2,2-dimethyl-3-[(E)-3-methylpent-3-enyl]oxirane
• CAS: 55874-06-1
• 化学式: C₁₀H₁₈O
• 分子量: 154.252
• InChiKey: QDRVJAQOGLBMLU-VMPITWQZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  12.5
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• Sesterterpene Compounds and Use Thereof
  申请人：Kang Heon Joong

  公开号：US20130274212A1

  公开（公告）日：2013-10-17

  The present invention relates to sesterterpene compounds, to the precursors thereof that are hydrolysable in a living body, or to the pharmaceutically acceptable salts thereof, and also relates to the prevention and treatment efficacy of the sesterterpene compounds with respect to non-insulin dependent diabetes mellitus, diabetic complications (renal failure and foot ulcers caused by diabetes), alcoholic, non-alcoholic, and viral fatty liver diseases, obesity, hyperlipidemia, atherosclerosis, cardiovascular diseases such as atherosclerotic stroke, and cerebropathies (Parkinsonism, schizophrenia and Alzheimer's disease). In addition, the present invention relates to compositions for functional foods, functional beverages, functional cosmetics, and functional feed.

  本发明涉及七萜化合物及其在生物体内可水解的前体物或其药学上可接受的盐，以及该七萜化合物在非胰岛素依赖性糖尿病、糖尿病并发症（由糖尿病引起的肾衰竭和足溃疡）、酒精性、非酒精性和病毒性脂肪肝疾病、肥胖症、高脂血症、动脉粥样硬化、动脉粥样硬化性中风、以及脑病（帕金森病、精神分裂症和阿尔茨海默病）的预防和治疗功效方面的应用。此外，本发明还涉及功能性食品、功能性饮料、功能性化妆品和功能性饲料的组合物。